{"entity":{"id":"bcg033","kind":"drug","name":"BCG033","aka":[],"tldr":"BCG033 is an experimental drug designed to carry chemotherapy to cancer cells. Its published evidence is from laboratory and animal studies.","summary":"AACR 2024 abstract 2616 describes BCG033 targeting PTK7 and TROP2. A vcMMAE construct with DAR 4 was tested in breast and lung xenografts; a separate BLD1102 TOP1 inhibitor construct with DAR 8 was tested in colorectal xenografts. These are distinct constructs, not a demonstrated dual-payload ADC. The cited results are preclinical and do not establish patient benefit.","status":"preclinical","asOf":"2026-10-06","links":[{"label":"Publisher abstract","url":"https://doi.org/10.1158/1538-7445.am2024-2616"}],"tags":["evidence:preclinical"],"related":[],"cancers":[],"sections":[],"technologies":["adc","bispecific-adc"],"targets":["trop2","ptk7"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"modality":"ADC","payload":"Separate tested constructs: vcMMAE (DAR 4) or TOP1 inhibitor BLD1102 (DAR 8)","mechanism":"Bispecific PTK7/TROP2 antibody-drug conjugate, tested with different single-payload conjugates rather than two payloads in one molecule.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/bcg033/","neighbours":{"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"bispecific-adc","kind":"technology","name":"Bispecific ADC","route":"/technologies/bispecific-adc/"}],"target":[{"id":"ptk7","kind":"target","name":"PTK7","route":"/targets/ptk7/"},{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}]}}